



# Genedrive®

## CYP2C19 ID Kit

Pharmacogenetic test to inform clinicians on an individual's CYP2C19 genotype and CPIC-coded metaboliser status

The **only** point-of-care genetic test to aid clinicians' therapeutic treatment decisions, for drugs that are metabolised by CYP2C19, and that are specifically affected by DNA variant alleles **\*2, \*3, \*4, \*8, \*17 and \*35**.



## Key Features



Supports personalised treatment using antiplatelet therapies



Non-invasive test, using buccal swabs



Rapid actionable results in approximately 69 minutes including diplotype and CPIC-coded metaboliser status



No cold storage required for reagents



Comprehensive variant coverage identifying clinically relevant alleles of CYP2C19 Loss of Function (\*2, \*3, \*4, \*8, \*35) and gain of function (\*17)

## The Clinical Need: Stroke

There are...

**100,000**

Strokes  
each year in  
the UK

**38,000**

UK annual  
stroke deaths

**£10.2B**

Estimated  
NHS cost of  
stroke by 2035

**5 minutes**

How often a stroke  
strikes in the UK



## Stroke Treatment

**Clopidogrel** is an antiplatelet treatment for secondary prevention of minor strokes and transient ischaemic attack (TIA), also known as a mini stroke.

CYP2C19 intermediate and poor metabolisers who receive clopidogrel experience reduced platelet inhibition and increased risk for major adverse cardiovascular and cerebrovascular events.

**£15M**

NHS England  
clopidogrel spend  
2022-2023

## NICE Recommendation

Use CYP2C19 genotyping to assess if clopidogrel is suitable for patients with ischaemic stroke or TIA.

The **Genedrive® CYP2C19 ID Kit** should be used as the point of care test of choice.



For more information,  
contact us at  
[enquiries@genedrive.com](mailto:enquiries@genedrive.com)



**genedrive**